Kensington Pharma Ltd 09543292 false 2023-05-01 2024-04-30 2024-04-30 The principal activity of the company is that of the wholesale of pharmaceutical goods. Digita Accounts Production Advanced 6.30.9574.0 true true 09543292 2023-05-01 2024-04-30 09543292 2024-04-30 09543292 core:CurrentFinancialInstruments 2024-04-30 09543292 core:CurrentFinancialInstruments core:WithinOneYear 2024-04-30 09543292 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-04-30 09543292 bus:SmallEntities 2023-05-01 2024-04-30 09543292 bus:AuditExemptWithAccountantsReport 2023-05-01 2024-04-30 09543292 bus:FullAccounts 2023-05-01 2024-04-30 09543292 bus:SmallCompaniesRegimeForAccounts 2023-05-01 2024-04-30 09543292 bus:RegisteredOffice 2023-05-01 2024-04-30 09543292 bus:Director1 2023-05-01 2024-04-30 09543292 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 09543292 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-05-01 2024-04-30 09543292 core:IntangibleAssetsOtherThanGoodwill 2023-05-01 2024-04-30 09543292 countries:AllCountries 2023-05-01 2024-04-30 09543292 2023-04-30 09543292 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-04-30 09543292 2022-05-01 2023-04-30 09543292 2023-04-30 09543292 core:CurrentFinancialInstruments 2023-04-30 09543292 core:CurrentFinancialInstruments core:WithinOneYear 2023-04-30 09543292 core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2023-04-30 iso4217:GBP xbrli:pure

Registration number: 09543292

Kensington Pharma Ltd

Unaudited Financial Statements

for the Year Ended 30 April 2024

 

Kensington Pharma Ltd

Contents

Statement of Financial Position

1

Notes to the Unaudited Financial Statements

2 to 6

 

Kensington Pharma Ltd

(Registration number: 09543292)
Statement of Financial Position as at 30 April 2024

Note

2024
£

2023
£

Fixed assets

 

Intangible assets

4

61,395

95,683

Current assets

 

Stocks

5

82,701

35,792

Debtors

6

320,177

279,387

Cash at bank and in hand

 

107,019

212,939

 

509,897

528,118

Creditors: Amounts falling due within one year

7

(996,320)

(1,268,136)

Net current liabilities

 

(486,423)

(740,018)

Net liabilities

 

(425,028)

(644,335)

Capital and reserves

 

Called up share capital

900

900

Retained earnings

(425,928)

(645,235)

Shareholders' deficit

 

(425,028)

(644,335)

For the financial year ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Income Statement.

Approved and authorised by the Board on 13 August 2024 and signed on its behalf by:
 

.........................................
Mr Iqbal Moosa
Director

   
     
 

Kensington Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

1

General information

The company is a private company limited by share capital, incorporated in England and wales .

The address of its registered office is:
Unit A Newlands House
60 Chain House Lane
Whitestake
Preston
Lancashire
PR4 4LG

These financial statements were authorised for issue by the Board on 13 August 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The Director acknowledges that at the year end the company's balance sheet shows net liabilities of £425,028 (2023: £644,335). The director believes that it is appropriate to prepare these accounts on a going concern basis since Hambleton (UK) Limited, a related company, has confirmed that it will provide continued financial support for the foreseeable future. The financial statements do not include any adjustments that would result if the financial support were to be withdrawn.

 

Kensington Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

Judgements

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows

-Determination of recoverability of trade debtors. A specific provision is made against certain debts where in the opinion of the directors the debt is not fully recoverable.

-Determination of recoverability of stock. A specific provision is made against certain stock where in the opinion of the directors the stock will be recovered at less than cost.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of
the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the
respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary
items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when
the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted

Intangible assets

Intangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated amortisation and impairment losses.

 

Kensington Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Asset class

Amortisation method and rate

Production Licences

20% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are measured at the lower of cost and net realisable value, after making due allowances for obsolete stock and slow moving items.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 1 (2023 - 2).

 

Kensington Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

4

Intangible assets

Product Licences
£

Total
£

Cost or valuation

At 1 May 2023

218,138

218,138

Disposals

(6,620)

(6,620)

At 30 April 2024

211,518

211,518

Amortisation

At 1 May 2023

122,455

122,455

Amortisation charge

27,668

27,668

At 30 April 2024

150,123

150,123

Carrying amount

At 30 April 2024

61,395

61,395

At 30 April 2023

95,683

95,683

5

Stocks

2024
£

2023
£

Finished goods

82,701

35,792

6

Debtors

Current

2024
£

2023
£

Trade debtors

309,926

242,820

Prepayments

10,251

36,567

 

320,177

279,387

 

Kensington Pharma Ltd

Notes to the Unaudited Financial Statements for the Year Ended 30 April 2024

7

Creditors

Creditors: amounts falling due within one year

2024
£

2023
£

Due within one year

Trade creditors

52,449

260,511

Taxation and social security

48,556

28,849

Accruals and deferred income

24,468

94,929

Other creditors

870,847

883,847

996,320

1,268,136

8

Related party transactions

At the year end the amount owing to Fontus Health Limited was £375,000 (2023:£295,000). Daljit Singh Birdi is a director of this company. No interest has been charged and the loan is repayable on demand.

At the year end the amount owing to Hambleton (UK) Limited was £495,514 (2023:£495,514). Iqbal Moosa is a director of this company. No interest has been charged and the loan is repayable on demand